Jared completed his doctorate in organic chemistry from Iowa State University of Science and Technology followed by a postdoctoral fellowship at the University of Michigan. He has been in the pharmaceutical industry for over 20 years as part of the process development group at Eli Lilly.
Jared has significant technical contributions and leadership across multiple projects as they prepared for commercialization and launch. Jared’s experience spans across both early and late-phase development and includes small molecules, peptides, insulins, and antibody drug conjugates. Currently Jared is leading drug substance development on Lilly’s core innovation portfolio as well as heavily involved with genotoxic impurity risk assessments and controls, regulatory interactions, and authoring of regulatory documents including the CTD drug substance CMC sections.